← Leaderboards
Rafal A Farjo
Charlesson, Llp
$4,717,138
Attributed
$4,717,138
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2008–13$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$4,717,138 · 5
By mechanism
R44$4,038,216 · 2
R43$678,922 · 3
Top collaborators
No co-investigators on record.
Most similar at Charlesson, Llp
Same institution · by research overlap
- Kangmo Lu$1,672,720
- Yan Feng$100,000
- Danyang Chen$3,659,618
Others in their field
Top investigators on “Retina”
- Keri Hammel · The Emmes Company, Llc$53,700,408
- Krzysztof Palczewski · University Of California-Irvine$48,214,939
- Adam R Glassman · Jaeb Center For Health Research, Inc.$47,242,041
- Cecilia Sungmin Lee · University Of Washington$32,086,169
- Adam Glassman · Jaeb Center For Health Research, Inc.$31,583,813
- Karen J Cruickshanks · University Of Wisconsin Madison$28,499,261
Research focus
RetinaInflammatoryInflammationRetinalPreventPharmaceutical PreparationsBlindnessAge Related Macular DegenerationExtravasationVascular Endothelial Growth FactorsChoroidal NeovascularizationDoseMediatingAngiogenesisMacular EdemaMonocyte Chemoattractant Protein-1Diabetic RatInjection Of Therapeutic AgentAnimal ModelCytokineDiabetes MellitusBlood-Retinal BarrierBlood VesselsIntercellular Adhesion Molecule 1
Grant awards (8)
Safety and Toxicology Studies of CLT-005 as a Therapeutic for Diabetic Macular Ed$680,041
R44 · FY2013 · EY · contact PI
Safety and Toxicology Studies of CLT-005 as a Therapeutic for Diabetic Macular Ed$873,711
R44 · FY2012 · EY · contact PI
Safety and Toxicology Studies of CLT-005 as a Therapeutic for Diabetic Macular Ed$1,095,787
R44 · FY2011 · EY · contact PI
Sustained delivery of linomide-5 for diabetic retinopathy and macular degeneratio$659,645
R44 · FY2009 · EY · contact PI
Development of a novel anti-inflammatory treatment for clinical management of end$227,286
R43 · FY2009 · EY · contact PI
Sustained delivery of linomide-5 for diabetic retinopathy and macular degeneratio$729,032
R44 · FY2008 · EY · contact PI
A novel Stat3 inhibitor for treating retinal inflammation and neovascularization$241,279
R43 · FY2008 · EY · contact PI
Development of a genetic CNV model for Age-Related Macular Degeneration$210,357
R43 · FY2008 · EY · contact PI